These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 20980697)

  • 1. Preserving the self: the process of decision making about hereditary breast cancer and ovarian cancer risk reduction.
    Howard AF; Balneaves LG; Bottorff JL; Rodney P
    Qual Health Res; 2011 Apr; 21(4):502-19. PubMed ID: 20980697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Women's decision making about risk-reducing strategies in the context of hereditary breast and ovarian cancer: a systematic review.
    Howard AF; Balneaves LG; Bottorff JL
    J Genet Couns; 2009 Dec; 18(6):578-97. PubMed ID: 19802692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality.
    Domchek SM; Friebel TM; Singer CF; Evans DG; Lynch HT; Isaacs C; Garber JE; Neuhausen SL; Matloff E; Eeles R; Pichert G; Van t'veer L; Tung N; Weitzel JN; Couch FJ; Rubinstein WS; Ganz PA; Daly MB; Olopade OI; Tomlinson G; Schildkraut J; Blum JL; Rebbeck TR
    JAMA; 2010 Sep; 304(9):967-75. PubMed ID: 20810374
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term outcomes of BRCA1/BRCA2 testing: risk reduction and surveillance.
    Schwartz MD; Isaacs C; Graves KD; Poggi E; Peshkin BN; Gell C; Finch C; Kelly S; Taylor KL; Perley L
    Cancer; 2012 Jan; 118(2):510-7. PubMed ID: 21717445
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Women's constructions of the 'right time' to consider decisions about risk-reducing mastectomy and risk-reducing oophorectomy.
    Howard AF; Bottorff JL; Balneaves LG; Kim-Sing C
    BMC Womens Health; 2010 Aug; 10():24. PubMed ID: 20687957
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
    Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
    Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of Risk-Reducing Salpingo-Oophorectomy With Breast Cancer Risk in Women With BRCA1 and BRCA2 Pathogenic Variants.
    Choi YH; Terry MB; Daly MB; MacInnis RJ; Hopper JL; Colonna S; Buys SS; Andrulis IL; John EM; Kurian AW; Briollais L
    JAMA Oncol; 2021 Apr; 7(4):585-592. PubMed ID: 33630024
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bilateral prophylactic oophorectomy and bilateral prophylactic mastectomy in a prospective cohort of unaffected BRCA1 and BRCA2 mutation carriers.
    Friebel TM; Domchek SM; Neuhausen SL; Wagner T; Evans DG; Isaacs C; Garber JE; Daly MB; Eeles R; Matloff E; Tomlinson G; Lynch HT; Tung N; Blum JL; Weitzel J; Rubinstein WS; Ganz PA; Couch F; Rebbeck TR
    Clin Breast Cancer; 2007 Dec; 7(11):875-82. PubMed ID: 18269778
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Breast and ovarian cancer risk perception after prophylactic salpingo-oophorectomy due to an inherited mutation in the BRCA1 or BRCA2 gene.
    Finch A; Metcalfe K; Lui J; Springate C; Demsky R; Armel S; Rosen B; Murphy J; Elit L; Sun P; Narod S
    Clin Genet; 2009 Mar; 75(3):220-4. PubMed ID: 19263514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Utilization of screening and preventive surgery among unaffected carriers of a BRCA1 or BRCA2 gene mutation.
    Wainberg S; Husted J
    Cancer Epidemiol Biomarkers Prev; 2004 Dec; 13(12):1989-95. PubMed ID: 15598752
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of decision aids for female BRCA1 and BRCA2 mutation carriers: a systematic review.
    Krassuski L; Vennedey V; Stock S; Kautz-Freimuth S
    BMC Med Inform Decis Mak; 2019 Aug; 19(1):154. PubMed ID: 31370837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer risk reduction and reproductive concerns in female BRCA1/2 mutation carriers.
    Staton AD; Kurian AW; Cobb K; Mills MA; Ford JM
    Fam Cancer; 2008; 7(2):179-86. PubMed ID: 18026853
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prophylactic surgery for women at high risk for breast cancer.
    Blanchard DK; Hartmann LC
    Clin Breast Cancer; 2000 Jul; 1(2):127-34; discussion 135. PubMed ID: 11899651
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Toward a new understanding of risk perception among young female BRCA1/2 "previvors".
    Hoskins LM; Roy KM; Greene MH
    Fam Syst Health; 2012 Mar; 30(1):32-46. PubMed ID: 22429077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Breast Cancer Risk Reduction Decisions of the BRCA-Positive Patient: An Observational Study at a Single Institution.
    Johns D; Agarwal J; Anderson L; Ying J; Kohlmann W
    J Womens Health (Larchmt); 2017 Jun; 26(6):702-706. PubMed ID: 27922795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comprehensive analysis of 989 patients with breast or ovarian cancer provides BRCA1 and BRCA2 mutation profiles and frequencies for the German population.
    Meindl A;
    Int J Cancer; 2002 Feb; 97(4):472-80. PubMed ID: 11802209
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of two evidence-based decision aids for female BRCA1/2 mutation carriers in Germany: study protocol for a randomised controlled parallel-group trial.
    Kautz-Freimuth S; Redaèlli M; Isselhard A; Shukri A; Vodermaier A; Rhiem K; Schmutzler R; Stock S
    Trials; 2022 Feb; 23(1):157. PubMed ID: 35172875
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Involvement and Influence of Healthcare Providers, Family Members, and Other Mutation Carriers in the Cancer Risk Management Decision-Making Process of BRCA1 and BRCA2 Mutation Carriers.
    Puski A; Hovick S; Senter L; Toland AE
    J Genet Couns; 2018 Sep; 27(5):1291-1301. PubMed ID: 29594659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Key messages for communicating information about BRCA1 and BRCA2 to women with breast or ovarian cancer: Consensus across health professionals and service users.
    Jacobs C; Pichert G; Harris J; Tucker K; Michie S
    Psychooncology; 2017 Nov; 26(11):1818-1824. PubMed ID: 28101941
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2.
    Gabai-Kapara E; Lahad A; Kaufman B; Friedman E; Segev S; Renbaum P; Beeri R; Gal M; Grinshpun-Cohen J; Djemal K; Mandell JB; Lee MK; Beller U; Catane R; King MC; Levy-Lahad E
    Proc Natl Acad Sci U S A; 2014 Sep; 111(39):14205-10. PubMed ID: 25192939
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.